Aptinyx to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The Cowen 41^st Annual Health Care Conference will feature CEO Norbert Riedel in the Neuropsychiatry Panel discussion on March 1, 2021. Additionally, the company will engage in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The neuropsychiatry discussion will be available for viewing on Aptinyx’s website for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:

• Cowen 41^st Annual Health Care Conference – Norbert Riedel, Ph.D., chief executive officer, will participate in the Neuropsychiatry Panel discussion at 1:20 p.m. EST on Monday, March 1, 2021; and

• H.C. Wainwright Global Life Sciences Conference – Senior management will participate in one-on-one meetings with investors throughout the conference on March 9 – 10, 2021.

The neuropsychology panel discussion will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005152/en/

FAQ

When is Aptinyx participating in the Cowen 41st Annual Health Care Conference?

Aptinyx will participate in the Cowen 41st Annual Health Care Conference on March 1, 2021.

Who will represent Aptinyx at the Cowen conference?

CEO Norbert Riedel will participate in the Neuropsychiatry Panel discussion.

What is the schedule for the H.C. Wainwright Global Life Sciences Conference?

Aptinyx will hold one-on-one meetings with investors on March 9-10, 2021 at the H.C. Wainwright Global Life Sciences Conference.

How can I view the Neuropsychiatry Panel discussion by Aptinyx?

The panel discussion can be viewed on the 'Events and Presentations' page of Aptinyx's website.

What is Aptinyx's focus in the biopharmaceutical industry?

Aptinyx focuses on developing therapies for brain and nervous system disorders using NMDA receptor modulators.